Table 4.
Surgical treatment in patients after neoadjuvant chemotherapy (NAC) versus primary surgery for in invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) patients
| Patients receiving NAC | Patients not receiving NAC | P value | |||
|---|---|---|---|---|---|
| Mastectomy | BCS | Mastectomy | BCS | ||
| ILC | 466 | 5935 | |||
| Clinical tumor size | |||||
| T1 | 18 (51.4) | 17 (48.6) | 1191 (36.6) | 2062 (63.4) | <0.0001 |
| T2 | 119 (61.7) | 74 (38.3) | 1352 (70.4) | 569 (29.6) | <0.0001 |
| T3 | 163 (89.1) | 20 (10.9) | 391 (95.6) | 18 (4.4) | <0.0001 |
| T4 | 52 (96.3) | 2 (3.7) | 40 (85.1) | 7 (14.9) | 0.0042 |
| All ILC patients | 353 (75.6) | 113 (24.4) | 3119 (52.5) | 2816 (47.5) | <0.0001 |
| IDC | 3622 | 40,975 | |||
|---|---|---|---|---|---|
| Clinical tumor size | |||||
| T1 | 208 (51.4) | 197 (48.6) | 7133 (26.8) | 19,449 (73.2) | <0.0001 |
| T2 | 840 (44.3) | 1056 (55.7) | 6106 (56.0) | 4803 (44.0) | <0.0001 |
| T3 | 590 (81.0) | 138 (19.0) | 528 (94.9) | 33 (5.1) | <0.0001 |
| T4 | 551 (94.0) | 35 (6.0) | 272 (89.9) | 31 (10.1) | 0.0262 |
| All IDC patients | 2196 (60.6) | 1426 (39.4) | 15,174 (37.0) | 25,801 (63.0) | <0.0001 |
Clinical tumor size was not known for 1 ILC and 7 IDC patients receiving NAC or for 266 ILC and 1721 IDC patients undergoing surgery without NAC
BCS breast-conserving surgery